Bio-Techne (BSP:T1CH34) Long-Term Capital Lease Obligation : R$457 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Long-Term Capital Lease Obligation?

Bio-Techne's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was R$457 Mil.

Bio-Techne's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (R$473 Mil) to Dec. 2024 (R$498 Mil) but then declined from Dec. 2024 (R$498 Mil) to Mar. 2025 (R$457 Mil).

Bio-Techne's annual Long-Term Capital Lease Obligation increased from Jun. 2022 (R$293 Mil) to Jun. 2023 (R$455 Mil) and increased from Jun. 2023 (R$455 Mil) to Jun. 2024 (R$472 Mil).

Bio-Techne Long-Term Capital Lease Obligation Historical Data

The historical data trend for Bio-Techne's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Long-Term Capital Lease Obligation Chart

Bio-Techne Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

348.91

340.05

293.44

455.11

471.92

Bio-Techne Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															461.89	471.92	473.11	497.94	457.48

Bio-Techne (BSP:T1CH34) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Bio-Techne Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TECH:USA

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines